Alteogen completes clinical trial of ‘Herceptin’ biosimilar
Alteogen announced the Phase 1 clinical trial of a biosimilar of Herceptin, a breast cancer therapy, which has been conducted in Canada since February, was successfully completed.
Alteogen has carried out the Phase 1 clinical trial after the company acquired its approval from ‘Health Canada’ las...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
